Six patients in our cohort benefited from a reduction of dosage interval to 3 weeks (group 3), showcasing mildly elevated serum IgE levels alongside elevated CRP, low vitamin D, elevated d-dimer, and positive anti-TPO and ANA, reminiscent of coexistent autoimmune and autoallergic endotype of urticaria. The gene discussed is BTG3; the disease is urticaria.